DOCSLIB.ORG

PI Narlaprevir in Russian Patients with Genotype 1 Chronic Hepatitis C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PI Narlaprevir in Russian Patients with Genotype 1 Chronic Hepatitis C The «second wave» PI Narlaprevir in Russian patients with genotype 1 chronic hepatitis C Professor Igor Bakulin Moscow Clinical Scientific Center June 5, 2015 Key points Background Narlaprevir in clinical trials Interim results of Phase III Russian PIONEER study Conclusions 11.06.2015 2 HCV Epidemiology in Russia Total population size1 143 000 000 Anti-HCV Ab-positive1 5 861 000 CHC diagnosed (viremic)1 1 789 500 New cases2 55 900/year AVT3 5 500*/year AVT – antiviral therapy; CHC – chronic hepatitis C 1 2010 data, Saraswat V, Norris S, et al. J Viral Hepat. 2015 ;22 Suppl 1:6-25; 2 Yuschuk ND, Znoyko OO, et al. Epidemiol Vaccine Prevent. 2013; 3 11.06.2015 Regional registries data, 2011 in Saraswat V, Norris S, et al. J Viral Hepat. 2015 ;22 Suppl3 1:6-25 *8 000/year according to IMS Health data calculated on the basis of PegIFN sales for all genotypes in 2014 Access to Direct Acting Antivirals in 2015 SMV SOF SMV No access to PR federal budget SOF SOF LDV Access to new DAA in DCV Russia and some other European countries is limited 3D/r EASL Monothematic Conference on “Liver Disease in Resource Limited Settings”, 2015 11.06.2015 4 EASL Recommendations 2015 IFN-free regimens Genotype Sofosbuvir + RBV 2, 3 Sofosbuvir/Ledipasvir (+/- RBV) 1, 4, 5, 6 Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir (+/- RBV) 1 Sofosbuvir + Simeprevir (+/- RBV) 1, 4 Sofosbuvir + Daclatasvir (+/- RBV) All Ombitasvir/Paritaprevir/Ritonavir (+/- RBV) 4 For countries with limited resources IFN-containing regimens are still relevant PegIFN-α + RBV + Sofosbuvir All PegIFN-α + RBV + Simeprevir 1, 4 11.06.2015 5 HCV Protease Inhibitors Value in Russia Protease inhibitors - a promising DAA group for the treatment of HCV 1b GT, the most prevalent genotype in Russia HCV Genotypes Protease inhibitors Asunaprevir Boceprevir Narlaprevir/r Paritaprevir/r Simeprevir Saraswat V, Norris S, de Knegt RJ, et al. J Viral Hepat. 2015;22 Suppl 1:6-25. Russian MoH Guidelines on HCV Diagnostics and Treatment in Adults. 2014. 11.06.2015 6 Key points Background Narlaprevir in clinical trials Preliminary results of Phase 3 first Russian PIONEER study Conclusions 11.06.2015 7 Narlaprevir – a new “second wave” PI • Oral HCV NS3 serine protease inhibitor (PI) • Reversible covalent binding with active NS3-protease site with ketoamid functional group • Ki = 7 ± 1 nМ, EC50 = 20 nМ, EC90 = 40 nМ • Mild cross-reactivity exists just with human cathepsin and neutrophyl elastase • No cross-reactivity with HIV-proteases Tong X et al. Antimicrob. Agents Chemother. 2010;54:2365-2370 11.06.2015 8 Extensive Clinical Program was Conducted by Merck/Schering-Plough Nearly 500 healthy volunteers and HCV-infected patients received at least one dose of Narlaprevir in completed clinical trials to date 9 Phase I Studies • 360 healthy volunteers and 32 chronic hepatitis C patients were exposed to at least one dose of Narlaprevir Phase IIa Study (NEXT-1) • 93 chronic hepatitis C patients were on Narlaprevir 11.06.2015 9 Increase in Narlaprevir Exposure after Standard Meal TabletTablet formulationFormulation ) 350 FastedFasted ng/mL FedFed ( 300 250 200 (ng/mL) 150 100 plasma concentration 50 SCH900518Plasma Concentration 0 0 2 4 6 8 10 12 14 16 18 20 22 24 Narlaprevir TimeTime (hours (hr) ) Narlaprevir administration under fed condition leads to increase in mean AUC(I) by 1,8 and Cmax by 2,8 compared to fasted state Reesink H.W., Bergmann J.F., et al., 2009, 50 (Suppl. 1), S35-S36. 11.06.2015 10 Low Doses of Ritonavir Significantly Increased Narlaprevir Exposure after Single Dosing mL) / Narlaprevir 400 mg alone ng ( Narlaprevir 400 mg with Ritonavir plasma concentration plasma concentration Narlaprevir Time (hours) Single Narlaprevir dosing in combination with Ritonavir leads to Narlaprevir AUC(I) and Cmax increase by 10 and 4 times, respectively, compared to single Narlaprevir dosing alone Reesink H.W., Bergmann J.F., et al., 2009, 50 (Suppl. 1), S35-S36. 11.06.2015 11 Phase 2а Study NEXT-1 Design HCV RNA <LOD on Week 4: PegIFN/RBV for 36 weeks PegIFN α2b (PegIFN)+ Ribavirin (RBV) Group 1 Control HCV RNA ≥LOD on Week 12: 200 mg Narlaprevir + 100 mg Ritonavir QD Group 2 Narlaprevir 400 mg + Ritonavir + PegIFN/RBV QD + PegIFN/RBV till 48 weeks 400 mg Narlaprevir + 100 mg Ritonavir QD Group 3 + PegIFN/RBV HCV RNA <LOD after 4 weeks 4 wks 200 mg Narlaprevir + 100 mg Ritonavir QD Group 4 NVR/r/PegIFN/RBV: PegIFN/RBV + PegIFN/RBV PegIFN/RBV for 12 weeks 4wks 400 mg Narlaprevir + 100 mg Ritonavir QD Group 5 HCV RNA ≥LOD after 4 weeks PegIFN/RBV + PegIFN/RBV NVR/r/PegIFN/RBV: 100 mg Narlaprevir + 100 mg Ritonavir BID PegIFN/RBV for 36 weeks Group 6 + PegIFN/RBV NVR/r – Narlaprevir + Ritonavir 12 weeks LOD – Low limit of detection Vierling J., Poordad F., et al. AASLD 2009. Boston. Oct 30-Nov 1, 2009. Abstract LB4. Vierling J., Poordad F., et al. Hepatology, 2011, 54, 1439A. 11.06.2015 12 Phase 2а Study NEXT-1 Baseline Patients Characteristics Most of patients were with genotype 1a and high viral load in all treatment groups Group 2 Group 3 Group 4 Group 5 Group 6 Group 1 NVR 200mg NVR 400mg LI + NVR LI + NVR NVR 100mg Control QD QD 200mg QD 400mg QD BID N=18 N=20 N=19 N=17 N=20 N=17 Male, % (n) 56 (10) 55 (11) 74 (14) 59 (10) 50 (10) 53 (9) White, % (n) 72 (13) 100 (20) 79 (15) 88 (15) 80 (16) 88 (15) Age (SD), years 46 (7) 43 (9) 45 (11) 45 (10) 46 (9) 46 (9) Weight (SD), kg 81 (20) 80 (11) 85 (10) 76 (17) 82 (18) 80 (18) BMI (SD), kg/m2 28 (6) 29 (4) 28 (2) 26 (5) 28 (4) 27 (5) Genotype 1а, % (n) 72 (13) 80 (16) 74 (14) 76 (13) 80 (16) 82 (14) Viral load 83 (15) 65 (13) 84 (16) 82 (14) 85 (17) 94 (16) >600 000 IU/mL, % (n) BMI – body mass index, LI – lead-in, NVR – narlaprevir, SD – standard deviation Vierling J., Poordad F., et al. AASLD 2009. Boston. Oct 30-Nov 1, 2009. Abstract LB4. Vierling J., Poordad F., et al. Hepatology, 2011, 54, 1439A. 11.06.2015 13 Phase 2а Study NEXT-1 High Antiviral Activity Mean HCV RNA decrease after 2 weeks of therapy exceeded 5 log10 IU/mL Narlaprevir was administered with Ritonavir 100 mg in all dosage groups * Including detected and non-detected HCV RNA < 25 IU/mL LLQ – low limit of quantification; NVR – narlaprevir; PegIFN – pegylated interferon alfa, RBV - ribavirin 11.06.2015 Vierling J., Poordad F., et al. AASLD 2009. Boston. Oct 30-Nov 1, 2009. Abstract14 LB4. Vierling J., Poordad F., et al. Hepatology, 2011, 54, 1439A. Phase 2а Study NEXT-1 Pharmacokinetics Narlaprevir* 200 mg QD Narlaprevir 400 mg QD Narlaprevir 100 mg BID Twice daily dosing and increased 400 mg dose didn’t give significant benefits for therapeutic concentration achievement compared to dose 200 mg once daily Time, hours * Narlaprevir was administered with Ritonavir 100 mg in all dosage groups Vierling J., Poordad F., et al. AASLD 2009. Boston. Oct 30-Nov 1, 2009. Abstract LB4. Vierling J., Poordad F., et al. Hepatology, 2011, 54, 1439A. 11.06.2015 15 Phase 2а Study NEXT-1 Sustained Virological Response 200 mg once daily without lead-in period group had the optimal SVR rate , % , % Patients * Narlaprevir was administered with Ritonavir 100 mg in all dosage groups LI – 4-week lead-in period; NVR – narlaprevir; PegIFN – pegylated interferon alfa; RBV – ribavirin; SVR – sustained virological response Vierling J., Poordad F., et al. AASLD 2009. Boston. Oct 30-Nov 1, 2009. Abstract LB4. Vierling J., Poordad F., et al. Hepatology, 2011, 54, 1439A. 11.06.2015 16 Phase 2а Study NEXT-1 Baseline Patients Characteristics Dosage groups with 200 mg Narlaprevir will be present on the next slide Group 2 Group 3 Group 4 Group 5 Group 6 Group 1 NVR NVR LI + NVR LI + NVR NVR Control 200mg QD 400mg QD 200mg QD 400mg QD 100mg BID N=18 N=20 N=19 N=17 N=20 N=17 Men, % (n) 56 (10) 55 (11) 74 (14) 59 (10) 50 (10) 53 (9) White, % (n) 72 (13) 100 (20) 79 (15) 88 (15) 80 (16) 88 (15) Age (SD), years 46 (7) 43 (9) 45 (11) 45 (10) 46 (9) 46 (9) Weight (SD), kg 81 (20) 80 (11) 85 (10) 76 (17) 82 (18) 80 (18) BMI (SD), kg/m2 28 (6) 29 (4) 28 (2) 26 (5) 28 (4) 27 (5) Genotype 1а, % (n) 72 (13) 80 (16) 74 (14) 76 (13) 80 (16) 82 (14) Viral load 83 (15) 65 (13) 84 (16) 82 (14) 85 (17) 94 (16) >600 000 IU/mL, % (n) BMI – body mass index, LI – lead-in, NVR – narlaprevir, SD – standard deviation Vierling J., Poordad F., et al. AASLD 2009. Boston. Oct 30-Nov 1, 2009. Abstract LB4. Vierling J., Poordad F., et al. Hepatology, 2011, 54, 1439A. 11.06.2015 17 Phase 2а Study NEXT-1 Safety Profile All adverse event rates were comparable to control PegIFN/RBV group Control Groups 2 + 4 Adverse events, % (n) PegIFN/RBV NVR 200 mg QD N=18 N=37 Fatigue 56 (10) 32 (12) Nausea 50 (9) 43 (16) Flu-like illness 44 (8) 16 (6) Headache 39 (7) 22 (8) Insomnia 39 (7) 30 (11) Anaemia 6 (1) 27 (10) Arthralgia 28 (5) 16 (6) Diarrhoea 17 (3) 14 (5) Pyrexia 17 (3) 14 (5) Irritability 28 (5) 19 (7) Pruritus 33 (6) 11 (4) Rash 11 (2) 3 (1) NVR – narlaprevir, PegIFN – pegylated interferon alfa; QD – once daily; RBV – ribavirin 11.06.2015 Vierling J., Poordad F., et al.
Load more

Recommended publications
  • HCV Protease
    HCV Protease HCV NS3-4A serine protease is a complex composed of NS3 and its cofactor NS4A. It harbours serine protease as well as NTPase/RNA helicase activities and is essential for viral polyprotein processing, RNA replication and virion formation. The HCV NS3/4A protease efficiently cleaves and inactivates two important signaling molecules in the sensory pathways that react to HCV pathogen-associated molecular patterns (PAMPs) to induce interferons (IFNs), i.e., mitochondrial antiviral signaling protein (MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF). HCV infection is associated with chronic liver disease, including hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma. The NS3-4A serine protease of HCV has been one of the most attractive targets for developing specific antiviral agents against HCV. www.MedChemExpress.com 1 HCV Protease Inhibitors & Antagonists ACH-806 Asunaprevir (GS9132) Cat. No.: HY-19512 (BMS-650032) Cat. No.: HY-14434 ACH-806 is an NS4A antagonist which can inhibit Asunaprevir (BMS-650032) is a potent and orally Hepatitis C Virus (HCV) replication with an bioavailable hepatitis C virus (HCV) NS3 protease EC50 of 14 nM. inhibitor, with IC50 of 0.2 nM-3.5 nM. Asunaprevir inhibits SARS-CoV-2 3CLpro activity. Purity: >98% Purity: 99.74% Clinical Data: No Development Reported Clinical Data: Launched Size: 1 mg, 5 mg Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg BI 653048 BI 653048 phosphate Cat. No.: HY-12946 Cat. No.: HY-12946A BI 653048 is a selective and orally active BI 653048 phosphate is a selective and orally nonsteroidal glucocorticoid (GC) agonist active nonsteroidal glucocorticoid with an IC50 value of 55 nM.
    [Show full text]
  • Direct-Acting Antiviral Medications for Chronic Hepatitis C Virus Infection
    Direct-Acting Antiviral Medications for Chronic Hepatitis C Virus Infection Alison B. Jazwinski, MD, and Andrew J. Muir, MD, MHS Dr. Jazwinski is a Fellow and Dr. Muir Abstract: Treatment of hepatitis C virus has traditionally been diffi- is an Associate Professor in the Division cult because of low rates of treatment success and high rates of treat- of Gastroenterology and Duke Clinical ment discontinuation due to side effects. Current standard therapy Research Institute at Duke University consists of pegylated interferon α and ribavirin, both of which have Medical Center in Durham, North Carolina. nonspecific and largely unknown mechanisms of action. New thera- pies are in development that act directly on the hepatitis C virus at various points in the viral life cycle. Published clinical trial data on these therapies are summarized in this paper. A new era of hepatitis Address correspondence to: C virus treatment is beginning, the ultimate goals of which will be Dr. Andrew J. Muir directly targeting the virus, shortening the length of therapy, improv- P.O. Box 17969 Durham, NC 27715; ing sustained virologic response rates, and minimizing side effects. Tel: 919-668-8557; Fax: 919-668-7164; E-mail: [email protected] epatitis C virus (HCV) is a major public health problem, with an estimated 180 million people infected worldwide. Up to 25% of chronically infected patients eventually Hdevelop cirrhosis and related complications, including hepatocellular carcinoma.1 Chronic liver disease secondary to HCV thus remains the leading indication for liver transplantation in the United States.2 The goal of HCV treatment is to eradicate the virus and pre- vent the development of cirrhosis and its complications.
    [Show full text]
  • Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize With
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.13.422511; this version posted December 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with 2 Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture 3 Khushboo Bafna1,#, Kris White2,#, Balasubramanian Harish3, Romel Rosales2, 4 Theresa A. Ramelot1, Thomas B. Acton1, Elena Moreno2, Thomas Kehrer2, 5 Lisa Miorin2, Catherine A. Royer3, Adolfo García-Sastre2,4,5,*, 6 Robert M. Krug6,*, and Gaetano T. Montelione1,* 7 1Department of Chemistry and Chemical Biology, and Center for Biotechnology and 8 Interdisciplinary Sciences, Rensselaer Polytechnic Institute, Troy, New York, 12180 9 USA. 10 11 2Department of Microbiology, and Global Health and Emerging Pathogens Institute, 12 Icahn School of Medicine at Mount Sinai, New York, NY10029, USA. 13 14 3Department of Biology, and Center for Biotechnology and Interdisciplinary Sciences, 15 Rensselaer Polytechnic Institute, Troy, New York, 12180 USA. 16 17 4Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at 18 Mount Sinai, New York, NY 10029, USA. 19 20 5The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 21 10029, USA 22 23 6Department of Molecular Biosciences, John Ring LaMontagne Center for Infectious 24 Disease, Institute for Cellular and Molecular Biology, University of Texas at Austin, 25
    [Show full text]
  • Curing Hepatitis C" by Gregory T
    6 ThE FUTURE of HCV TREATMENT Beyond Triple Therapy I am still on treatment and almost halfway through the trial. I do not have hepatitis C at the present time. I hope this treatment has cured it, and I hope I will not need future treatment. The results were immediate. Before I began the QUAD Therapy clinical trial, there were over four million copies of the virus per milliliter of my blood. After the first week, that was down to only 160 copies per milliliter, and, at week two, I tested negative for hepatitis C. The virus is still undetectable in my blood—hopefully, this is it, and I am cured. — Mark Tw e n ty year s ago, I treated patients with HCV genotype 1 infection with interferon monotherapy, and five percent achieved SVR. Results improved to an SVR of 45 percent with peginterferon/ribavirin. Now, the new standard of care of triple therapy is expected to raise SVR up to 75 percent. What’s next? In this chapter, I look to the future, focusing on the next generation of direct-acting antivirals: new protease inhibitors, polymerase inhibitors, From "Curing Hepatitis C" by Gregory T. Everson Reprinted with permission— 115 by Hatherleigh— Press ISBN: 978-1-57826-425-4 Available wherever books are sold 116 CUR in G H E PA titis C NS5A inhibitors, and others. The future for treating HCV is, indeed, bright. Hopefully, the time will soon arrive when nearly every person infected with HCV will have safe, tolerable, and effective options for treatment. The year 2011 marked the beginning of a new era in the treatment of the hepatitis C virus (HCV) with the introduction of telaprevir and boceprevir.
    [Show full text]
  • 13. Approved and Experimental Therapies
    APPROVED AND EXPERIMENTAL THERAPIES FOR TREATMENT OF HEPATITIS B AND C, AND MUTATIONS 13. ASSOCIATED WITH DRUG RESISTANCE • Luis Menéndez-Arias HEPATITIS B Table 13.1. CURRENT DRUGS FOR TREATMENT OF HEPATITIS B Drug name Drug class Manufacturer Status Pegasys (peginterferon α-2a) Interferon Genentech FDA-approved Intron A (interferon a-2b) Interferon Merck FDA-approved Hepsera (adefovir Nucleotide analogue Gilead Sciences FDA-approved dipivoxil)a Viread (tenofovir Nucleotide analogue Gilead Sciences FDA-approved b disoproxil fumarate) a Epivir-HBV, Zeffix and Nucleoside analogue Glaxo SmithKline FDA-approved Heptodin (lamivudine) a Baraclude (entecavir) Nucleoside analogue Bristol-Myers Squibb FDA-approved Tyzeka, Sebivo Nucleoside analogue Novartis FDA-approved (telbivudine) Vemlidy (TAF, tenofovir Tenofovir prodrug Gilead Sciences FDA-approved alafenamide, GS-7340) Emtriva (emtricitabine; Nucleoside analogue Gilead Sciences FDA-approved b FTC) a Levovir, Revovir Nucleoside analogue Bukwang Studies cancelled c (clevudine, L-FMAU) pharmaceuticals, Eisai (Japan) Besivo (LB80380, Nucleoside analogue IIDong Pharmaceutical Approved in S ANA380) Co. Ltd. Korea Zadaxin (thymosin alpha) Immune enhancer SciClone Approved outside U.S. ABX 203 Therapeutic vaccine ABIVAX Phase IIb/III ARC-520 RNAi gene silencer Arrowhead Research Phase II/III 641 Drug name Drug class Manufacturer Status Myrcludex B Entry inhibitor Hepatera (Russia), Phase IIa Myr-Gmbh (Germany) (Russia) NVR-1221 (NVR 3-778) Capsid inhibitor Novira Therapeutics Phase IIa AGX-1009
    [Show full text]
  • Structural Basis for the Inhibition of the SARS-Cov-2 Main Protease by the Anti-HCV Drug Narlaprevir
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans LETTER OPEN Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir Signal Transduction and Targeted Therapy (2021) ;6:51 https://doi.org/10.1038/s41392-021-00468-9 Dear Editor, 21 μM and 0.46 μM, respectively (Supplementary Fig. S1). These The second wave of the coronavirus disease (COVID-19) results were consistent with the enzyme activity inhibition assay. pandemic has recently appeared in Europe. Most European Narlaprevir showed an antiviral effect against SARS-CoV-2 with countries, such as France, Germany, and Italy, have announced an EC50 value of 7.23 μM (Fig. 1b). As a positive control, remdesivir the implementation of a new round of epidemic prevention and and boceprevir inhibited SARS-CoV-2 replication with EC50 values control measures. However, no clinical drug or vaccine has been of 0.58 μM and 14.13 μM, respectively. Additionally, narlaprevir approved for the treatment of COVID-19. The interim results of the exhibited no cytotoxicity in Vero cells at different concentrations solidarity therapy trial coordinated by the World Health Organiza- up to 200 μM (Supplementary Fig. S2). Treatment with narlaprevir tion (WHO) indicated that remdesivir, hydroxychloroquine, lopina- infection demonstrated a dose-dependent inhibitory effect on vir/ritonavir, and interferon appear to have little or no effect on the SARS-CoV-2 plaque formation (Fig. 1c). The plaques were 28-day mortality of hospitalized patients or the hospitalization completely inhibited in the presence of 50 μM narlaprevir. process of new COVID-19 patients.
    [Show full text]
  • Tetrazolones As Inhibitors of Fatty Acid Synthase Tetrazolone Als Fettsäuresynthasehemmer Tétrazolones Utilisés En Tant Qu’Inhibiteurs D’Acide Gras Synthase (Fasn)
    (19) TZZ ¥_T (11) EP 2 566 853 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 257/04 (2006.01) C07D 401/06 (2006.01) 25.01.2017 Bulletin 2017/04 C07D 401/12 (2006.01) C07D 403/06 (2006.01) C07D 403/12 (2006.01) C07D 407/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11731538.2 C07D 413/06 C07D 413/12 C07D 417/04 (2006.01) C07D 417/06 (2006.01) A61K 31/41 (2006.01) A61P 3/00 (2006.01) (22) Date of filing: 04.05.2011 A61P 29/00 (2006.01) A61P 35/00 (2006.01) (86) International application number: PCT/US2011/035141 (87) International publication number: WO 2011/140190 (10.11.2011 Gazette 2011/45) (54) TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE TETRAZOLONE ALS FETTSÄURESYNTHASEHEMMER TÉTRAZOLONES UTILISÉS EN TANT QU’INHIBITEURS D’ACIDE GRAS SYNTHASE (FASN) (84) Designated Contracting States: • KEANEY, Gregg, F. AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Lexington GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO MA 02421 (US) PL PT RO RS SE SI SK SM TR • NEVALAINEN, Marta Weymouth (30) Priority: 02.12.2010 US 419174 P MA 02189 (US) 06.04.2011 US 472566 P • NEVALAINEN, Vesa 28.01.2011 US 437564 P Weymouth 05.05.2010 US 331644 P MA 02189 (US) 05.05.2010 US 331575 P • PELUSO, Stephane Brookline (43) Date of publication of application: MA 02446 (US) 13.03.2013 Bulletin 2013/11 • SNYDER, Daniel, A.
    [Show full text]
  • DRAFT: Targeting SARS-Cov-2 M3clpro by HCV Ns3a/4 Inhibitors: in Silico Modeling and in Vitro Screening
    DRAFT: Targeting SARS-CoV-2 M3CLpro by HCV NS3a/4 Inhibitors: In Silico Modeling and In Vitro Screening. Anjela Manandhar1, Benjamin E Blass2, Dennis J Colussi2, Imane Almi2,3, Magid Abou-Gharbia2, Michael L. Klein1, Khaled M. Elokely1* 1Institute for Computational Molecular Science and Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, United States 2 Department of Pharmaceutical Sciences, Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Philadelphia, Pennsylvania 19140, United States 3 Group of Computational and Pharmaceutical Chemistry, LMCE Laboratory, University of Biskra, BP 145 Biskra, 07000, Algeria Corresponding author: Khaled M. Elokely - Institute for Computational Molecular Science and Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, United States Email: [email protected] ABSTRACT Currently the entire human population is in the midst of a global pandemic caused by SARS-CoV- 2 (Severe Acute Respiratory Syndrome–CoronaVirus-2). This highly pathogenic virus has to date caused >71 million infections and >1.6 million deaths in >180 countries. Several vaccines and drugs are being studied as possible treatment or prophylactics of this viral infection. M3CLpro (coronavirus main cysteine protease) is a promising drug target as it has a significant role in viral replication. Here we use the X-ray crystal structure of M3CLpro in complex with Boceprevir to study the dynamic changes of the protease upon ligand binding. The binding free energy was calculated for water molecules at different locations of the binding site, and molecular dynamics (MD) simulations were carried out for the M3CLpro/Boceprevir complex, to thoroughly understand the chemical environment of the binding site.
    [Show full text]
  • Repurposing of FDA Approved Drugs
    Antiviral Drugs (In Phase IV) ABACAVIR GEMCITABINE ABACAVIR SULFATE GEMCITABINE HYDROCHLORIDE ACYCLOVIR GLECAPREVIR ACYCLOVIR SODIUM GRAZOPREVIR ADEFOVIR DIPIVOXIL IDOXURIDINE AMANTADINE IMIQUIMOD AMANTADINE HYDROCHLORIDE INDINAVIR AMPRENAVIR INDINAVIR SULFATE ATAZANAVIR LAMIVUDINE ATAZANAVIR SULFATE LEDIPASVIR BALOXAVIR MARBOXIL LETERMOVIR BICTEGRAVIR LOPINAVIR BICTEGRAVIR SODIUM MARAVIROC BOCEPREVIR MEMANTINE CAPECITABINE MEMANTINE HYDROCHLORIDE CARBARIL NELFINAVIR CIDOFOVIR NELFINAVIR MESYLATE CYTARABINE NEVIRAPINE DACLATASVIR OMBITASVIR DACLATASVIR DIHYDROCHLORIDE OSELTAMIVIR DARUNAVIR OSELTAMIVIR PHOSPHATE DARUNAVIR ETHANOLATE PARITAPREVIR DASABUVIR PENCICLOVIR DASABUVIR SODIUM PERAMIVIR DECITABINE PERAMIVIR DELAVIRDINE PIBRENTASVIR DELAVIRDINE MESYLATE PODOFILOX DIDANOSINE RALTEGRAVIR DOCOSANOL RALTEGRAVIR POTASSIUM DOLUTEGRAVIR RIBAVIRIN DOLUTEGRAVIR SODIUM RILPIVIRINE DORAVIRINE RILPIVIRINE HYDROCHLORIDE EFAVIRENZ RIMANTADINE ELBASVIR RIMANTADINE HYDROCHLORIDE ELVITEGRAVIR RITONAVIR EMTRICITABINE SAQUINAVIR ENTECAVIR SAQUINAVIR MESYLATE ETRAVIRINE SIMEPREVIR FAMCICLOVIR SIMEPREVIR SODIUM FLOXURIDINE SOFOSBUVIR FOSAMPRENAVIR SORIVUDINE FOSAMPRENAVIR CALCIUM STAVUDINE FOSCARNET TECOVIRIMAT FOSCARNET SODIUM TELBIVUDINE GANCICLOVIR TENOFOVIR ALAFENAMIDE GANCICLOVIR SODIUM TENOFOVIR ALAFENAMIDE FUMARATE TIPRANAVIR VELPATASVIR TRIFLURIDINE VIDARABINE VALACYCLOVIR VOXILAPREVIR VALACYCLOVIR HYDROCHLORIDE ZALCITABINE VALGANCICLOVIR ZANAMIVIR VALGANCICLOVIR HYDROCHLORIDE ZIDOVUDINE Antiviral Drugs (In Phase III) ADEFOVIR LANINAMIVIR OCTANOATE
    [Show full text]
  • Criteria Grid Best Practices and Interventions for the Diagnosis and Treatment of Hepatitis C
    Criteria Grid Best Practices and Interventions for the Diagnosis and Treatment of Hepatitis C Best Practice/Intervention: Chevaliez S. et al. (2011) Mechanisms of non‐response to antiviral treatment in chronic hepatitis C. Clinics & Research in Hepatology & Gastroenterology, 35(Suppl 1):31‐41. Date of Review: February 8, 2015 Reviewer(s): Christine Hu Part A Category: Basic Science Clinical Science Public Health/Epidemiology Social Science Programmatic Review Best Practice/Intervention: Focus: Hepatitis C Hepatitis C/HIV Other: Level: Group Individual Other: Target Population: people with HCV infection Setting: Health care setting/Clinic Home Other: Country of Origin: France Language: English French Other: Part B YES NO N/A COMMENTS Is the best practice/intervention a meta‐analysis or Overview of the mechanisms involved in primary research? non‐response (lack of sustained virological response) to the current and future standard treatment of chronic hepatitis C infection through the use of published data The best practice/intervention has utilized an evidence‐based approach to assess: Efficacy Effectiveness The best practice/intervention has been evaluated in more than one patient setting to assess: Efficacy Effectiveness YES NO N/A COMMENTS The best practice/intervention has been Articles referenced may originate from operationalized at a multi‐country level: various countries. There is evidence of capacity building to engage individuals to accept treatment/diagnosis There is evidence of outreach models and case studies to improve access
    [Show full text]
  • New Treatment Approaches and Cure Strategies
    Hepatitis C: New Therapies in 2016-2017 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and Gastroenterology/Hepatology Baltimore, Maryland Current HCV direct acting antiviral regimens cure the majority of persons treated in phase 3 trials Highly efficacious DAAs target New England Journal of Medicine trials in GT 1 1 Receptor binding different points in the HCV lifecycle published in 20142 and endocytosis Transport 96% and release Fusion and uncoating Virion assembly (+) RNA ER lumen Translation and LD polyprotein LD processing NS5A inhibitors LD 3680/ Membranous 3826 web RNA replication ER lumen Sustained Virologic NS3 protease inhibitors Nucleos(t)ide and Non- Response nucleoside NS5B inhibitors [SVR] 1. Lindenbach BD, Rice CM. Nature 2005;436(Suppl):933–8; 2. Liang J, Ghany MG. N Engl J Med 2014;370:2043–7; 3. Burki T. Lancet Infect Dis 2014;14:452–3 Globally, 150 million people are infected with hepatitis C and 350,000 to 500,000 people die each year Messina JP et al, Hepatology, 2015; 61: 77-87. WHO Global Health Sector HCV Strategy Global targets for 2030 Reduce Expand and Decrease new Decrease global enhance services infections deaths suffering and costs • 90% diagnosed • 70% reduction in • 60% reduction in • 90% of eligible HCV incidence HCV-related deaths people treated • 50% reduction by • 90% of those treated 2020 are cured • Zero new infections • 50% of PWID due to unsafe blood covered by harm transfusions reduction services • 75% reduction in by 2020 new infections due to unsafe medical practices by 2020 WHO.
    [Show full text]
  • CER 76: Treatment for Hepatitis C Virus Infection in Adults
    Comparative Effectiveness Review Number 76 Treatment for Hepatitis C Virus Infection in Adults Comparative Effectiveness Review Number 76 Treatment for Hepatitis C Virus Infection in Adults Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. 290-2007-10057-I Prepared by: Oregon Evidence-based Practice Center Oregon Health & Science University Portland, OR Investigators: Roger Chou, M.D. Daniel Hartung, Pharm.D., M.P.H. Basmah Rahman, M.P.H. Ngoc Wasson, M.P.H. Erika Cottrell, Ph.D. Rongwei Fu, Ph.D. AHRQ Publication No. 12(13)-EHC113-EF November 2012 This report is based on research conducted by the Oregon Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10057-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.
    [Show full text]